PharmiWeb.com - Global Pharma News & Resources
19-Dec-2018

Estrogen Receptor Beta Partial Agonist Pipeline Insights, 2018 Report Featuring Ausio Pharmaceuticals, AstraZeneca, ENDECE, ACADIA Pharmaceuticals & Eli Lilly - ResearchAndMarkets.com

The "Estrogen Receptor Beta Partial Agonist -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Estrogen Receptor Beta Partial Agonist - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Estrogen Receptor Beta Partial Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Estrogen Receptor Beta Partial Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Estrogen Receptor Beta Partial Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Ausio Pharmaceuticals
  • AstraZeneca
  • ENDECE
  • ACADIA Pharmaceuticals
  • Eli Lilly

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/8kf5w2/estrogen_receptor?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181219005753/en/

Editor Details

Last Updated: 19-Dec-2018